ENTA — Enanta Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $119.04m
- -$96.31m
- $67.64m
- 41
- 39
- 51
- 39
Annual income statement for Enanta Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 122 | 97.1 | 86.2 | 79.2 | 67.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 164 | 207 | 210 | 216 | 189 |
| Operating Profit | -41.6 | -110 | -124 | -137 | -122 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -35 | -108 | -122 | -131 | -118 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -36.2 | -79 | -122 | -134 | -116 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -36.2 | -79 | -122 | -134 | -116 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -36.2 | -79 | -122 | -134 | -116 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 |